PPD to Discover Biomarkers for PDL BioPharma
News May 03, 2006
Under the terms of the agreement, PPD's biomarker discovery sciences group will examine specified sample sets utilizing DeepLook™ analysis, its proprietary integrated platform for mass spectrometry-based discovery of biomarkers.
"Identification and implementation of biomarkers can accelerate clinical trials by improving diagnosis, patient selection, and monitoring of disease progression and therapeutic response," said Howard Schulman, vice president of PPD's biomarker discovery sciences.
"We look forward to working with PDL BioPharma to develop biomarkers for its clinical development programs."
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.